Notably, non-squamous NSCLC patients with KRAS mutations benefited from nivolumab therapy in terms of overall survival, whereas KRAS wild-type patients did not (Borghaei et al., 2015). The gene discussed is KRAS; the disease is non-small cell lung carcinoma.